EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reprogramming Listeria monocytogenes flavin metabolism to improve its therapeutic safety profile and broaden innate T-cell activation

Victoria Chevée, Mariya Lobanovska iD, Rafael Rivera-Lugo, Leslie Güereca, Ying Feng, Andrea Anaya-Sanchez, Jesse Garcia Castillo, Austin M Huckins, Edward E Lemmens, Chris S Rae, Jonathan W Hardy iD, Russell Carrington und 2 weitere

mBio · 2026

DOI: 10.1128/mbio.03652-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2026. Verfasst von Victoria Chevée und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, USA. Hauptthemen laut MEDLINE: Listeria monocytogenes, T-Lymphocytes, Lymphocyte Activation, Flavins. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, ORFDO NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Listeria monocytogenes is a facultative intracellular bacterial pathogen that is a potent inducer of cell-mediated immunity, which has led to the development of attenuated, Listeria -based cancer vaccines. L. monocytogenes strains, such as live-attenuated double-deleted Listeria (LADD), lacking two key virulence factors, Δ actA and Δ inlB , have been used safely in clinical trials and showed promising anti-tumor activity. Despite early clinical success, improving potency and safety by preventing extracellular bacterial growth is paramount for the development of further clinical applications. We describe a quadruple attenuated intracellular Listeria (QUAIL) strain that, in addition to Δ actA Δ inlB, lacks ribC and ribF , which encode enzymes required for generating the essential flavin cofactors flavin mononucleotide (FMN) and flavin adenine nucleotide (FAD). QUAIL imported FMN and FAD during intracellular growth but was unable to grow extracellularly in blood or on vascular catheters in mice, which reduced its lethality. Despite its lack of extracellular growth, QUAIL maintained its immunoprotective properties, which were comparable to LADD. Furthermore, we showed that QUAIL can be engineered to synthesize riboflavin, leading to expansion and activation of mucosal-associated invariant T cells. Together, our data support the use of QUAIL as a promising therapeutic platform with an improved safety profile that is amenable to further modifications to expand its immune-activating potential. IMPORTANCE Listeria -based live-attenuated cancer vaccines represent a promising therapy in many different pre-clinical tumor models and in clinical trials. Enhancing its anti-cancer immunity and increasing its safety profile will advance the clinical applications of Listeria vaccines. By manipulating Listeria monocytogenes flavin metabolism, we engineered a quadruple attenuated intracellular Listeria (QUAIL) vaccine candidate strain that has limited toxicity associated with extracellular growth in major extracellular niches in vivo, including blood and implanted catheter ports. Furthermore, we showed that QUAIL can be effectively programmed to engage innate-like T cells known as mucosal-associated invariant T cells, which could be harnessed for future cancer immunotherapies. The results presented here lay the foundation for further analysis of QUAIL as a safer, yet immunopotent L. monocytogenes vaccine or therapeutic vector.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Listeria monocytogenesT-LymphocytesLymphocyte ActivationFlavinsAnimalsMiceVaccines, AttenuatedListeriosisFemaleImmunity, InnateCancer VaccinesMice, Inbred C57BLFlavin-Adenine Dinucleotide

Stichwörter der Autor:innen

Listeria monocytogenesMAIT cellsflavinsimmunotherapeuticsvaccines

Substanzen

Vaccines, AttenuatedFlavinsCancer VaccinesFlavin-Adenine Dinucleotide

Autor:innen und Institutionen

  • Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, USA.
  • Department of Plant and Microbial Biology, University of California Berkeley, Berkeley, California, USA.
  • Department of Microbiology, Genetics, & Immunology, Michigan State University, East Lansing, Michigan, USA.
  • Laguna Biotherapeutics, San Francisco, California, USA.

ORCID-Profile: Mariya Lobanovska, Jonathan W Hardy, Daniel A Portnoy

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • ORFDO NIH HHS
  • NCI NIH HHS
  • NIDA NIH HHS

Zitieren

APA

Chevée, V., Lobanovska, M., Rivera-Lugo, R., Güereca, L., Feng, Y., Anaya-Sanchez, A., Garcia Castillo, J., Huckins, A. M., Lemmens, E. E., Rae, C. S., Hardy, J. W., Carrington, R., Kotula, J. W., & Portnoy, D. A. (2026). Reprogramming Listeria monocytogenes flavin metabolism to improve its therapeutic safety profile and broaden innate T-cell activation. mBio. https://doi.org/10.1128/mbio.03652-25

Vancouver

Chevée V, Lobanovska M, Rivera-Lugo R, Güereca L, Feng Y, Anaya-Sanchez A, et al. Reprogramming Listeria monocytogenes flavin metabolism to improve its therapeutic safety profile and broaden innate T-cell activation. mBio. 2026. doi:10.1128/mbio.03652-25

BibTeX
@article{Cheve2026,
  author = {Chevée, Victoria and Lobanovska, Mariya and Rivera-Lugo, Rafael and Güereca, Leslie and Feng, Ying and Anaya-Sanchez, Andrea and Garcia Castillo, Jesse and Huckins, Austin M and Lemmens, Edward E and Rae, Chris S and Hardy, Jonathan W and Carrington, Russell and Kotula, Jonathan W and Portnoy, Daniel A},
  title = {Reprogramming Listeria monocytogenes flavin metabolism to improve its therapeutic safety profile and broaden innate T-cell activation},
  journal = {mBio},
  year = {2026},
  doi = {10.1128/mbio.03652-25}
}
Kostenlos starten →